APTO News and Press, Aptose Biosciences Inc. From 03/22/22

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway into fourth quarter of 2023 - - Conference call and webcast at 5:00 pm ET to...

Aptose Biosciences (NASDAQ:APTO) is scheduled to announce Q4 earnings results on Tuesday, March 22nd, after market close. The consensus EPS Estimate is -$0.17 Over the last 3 months, EPS estimates have seen 1 upward revision and 2 downward. For further details see: Aptose Biosciences Q4...

ADBE, AIR, APTO, AVGR, CLBS, GAN, HQY, OTCQB:NEXCF, PAGS, PAYS, POSH, SLDP, WOR, ZY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and q...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! In preparation for another busy day of trading, we’ve put together a list of the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com We’ve got ear...

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, Presiden...

A lack of progress in the clinic, including another disappointing ASH meeting, has led investors to bail out of this risky early-stage biotech. A new formulation of luxeptinib, and potentially greater exposure to the drug, may finally unlock the potential of this once-promising drug, ...

— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today...

-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline -- SAN DIEGO and TORONTO, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) ...

Aptose Biosciences (TSX:APS) (NASDAQ:APTO) shares climbed 17% on Thursday after losing up to 45% earlier this week. This came after the company announced results from its leukemia drug trial. What happened? Shares of Aptose were already in free fall before this recen...